• Home
• Dabigatran
• Denosumab
• Dronedarone
• Edoxaban
• Lisdexamfetamine
• Rifaximin
• Contact Us

Back to Keele University
School of Pharmacy and Bioengineering

Edoxaban (Lixiana^®)
Last Updated: 20th January, 2017

This Effective Shared Care Agreement Toolkit (edoxaban [Lixiana^®]) is designed to assist healthcare professionals in the development of their own shared care agreements to support locally agreed policy on the prescribing of edoxaban for the prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation. In particular, it suggests ways in which responsibilities can be shared between the secondary care specialist and general practitioner (GP) / primary care prescriber. The Toolkit is intended to act as a flexible template that enables users to consider suggested content and tailor it to local circumstances and requirements.

Please note that the Effective Shared Care Agreement Toolkit is not a recommendation to prescribe edoxaban. The decision to prescribe edoxaban is the responsibility of the respective local healthcare organisation and the Toolkit should only be used after the local decision to prescribe edoxaban has been taken.

To support your local decision-making you may wish to refer to:

• Edoxaban Summary of Product Characteristics (SPC) (60mg and 30mg)
• Edoxaban Patient Information Leaflet
• Edoxaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation. NICE technology appraisal guidance [TA355]. September 2015.
• Atrial fibrillation: management. NICE Clinical guideline [CG180]. June 2014.
• Anticoagulation therapy for the prevention of stroke and systemic embolism in atrial fibrillation. Decision Support Tool.
• Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation (Executive summary, June 2016)
• Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Daiichi Sankyo UK Medical Information on 0800 028 5122, medInfo@daiichi-sankyo.co.uk

Further support materials are available from the manufacturer:

• Prescriber Guide
• Patient Alert Card

The Effective Shared Care Agreement Toolkit and Keele University's work in developing shared care resources has been recognised by the General Medical Council in their guidance 'Good practice in prescribing and managing medicines and devices' (January 2013).

Keele University is not responsible for the content of any linked site or manufacturer's material. Listing and linking should not be taken as an endorsement of any kind and we accept no liability in respect of the content.

Enter the
ESCA Toolkit

Agreement Library

Upload an existing agreement to the library here.

Sponsor

Supported by an unrestricted grant provided by Daiichi-Sankyo in the UK